Clinical trials: HEPATITIS C VIRUS CHRONIC INFECTION
Hepatitis C
Macrophage Activation Markers During Sofosbuvir-based Treatment Regimes of Chronic Hepatitis C
The purpose of the study is to investigate how the liver is affected with regard to inflammation and fibrosis during Sofosbuvir based treatment regimes of chronic hepatitis C.
- Trial name
- NCT02528461
- Testing
- Galactose, Gastroscopy, Liver biopsy
- Where
- Denmark
- Volunteers
- 71 people
- Sponsor
- University of Aarhus
Chronic Hepatitis C
Role of the Host Immunity in the Non-response to Direct Anti-viral Agent (DAA) Therapy
Anti-viral, hepatitis C virus (HCV)-specific immune T cell responses are functionally defective in patients with chronic hepatitis C and this functional impairment is believed to contribute to virus persistence.
- Trial name
- NCT03155113
- Testing
- blood drawing
- Where
- Italy
- Volunteers
- 77 people
- Sponsor
- Azienda Ospedaliero-Universitaria di Parma
Chronic Hepatitis c
Evaluation of the Efficacy and Safety of the Fixed-dose Combination Sofosdac® 400mg/60mg in Patients With Chronic Hepatitis C (HCV)
A multicentric, observational, open-design study conducted to evaluate the efficacy and safety of Sofosdac® 400mg/60mg tablets treatment in 100 patients with chronic hepatitis C (HCV)
- Trial name
- NCT05138523
- Testing
- Sofosdac®
- Where
- 4 sites in Algeria
- Volunteers
- 99 people
- Sponsor
- Beker Laboratories
Hepatitis C, Chronic
Post Marketing Observational Study of Retreatment of Chronic Hepatitis C With Peginterferon Alpha and Ribavirin (Study P06011)
To study retreatment in patients who failed prior treatment with interferon alpha (pegylated or non-pegylated) with or without ribavirin in a real-life setting in an observational/noninterventional study.
- Trial name
- POMOSCH (NCT01098097)
- Testing
- Peginterferon alpha, Ribavirin
- Volunteers
- 963 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C, Chronic
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755)
The primary purpose of this study is to compare the efficacy of two boceprevir (BOC)-containing therapeutic regimens in the treatment of naïve participants with chronic hepatitis C virus (HCV) genotype 1 who have the IL28B CC…
- Trial name
- NCT01544920
- Testing
- peg-Interferon alfa-2a, Ribavirin, Boceprevir
- Volunteers
- 737 people
- Sponsor
- Merck Sharp & Dohme LLC
Liver Cirrhoses, Chronic Hepatitis c
Hematologic Profile, Vit. B12 and Folic Acid in Cirrhotics Received Sofosbuvir and Daclatasvir With or Without Ribavirin
Use of Ribavirin could affect hematologic profile of the patients negatively. With advent of new antiviral therapy, the preexisting hematologic changes may alter or corrected after treatment.
- Conditions
- Liver Cirrhoses, Chronic Hepatitis c, Directly Acting Antivirals
- Trial name
- NCT03283176
- Testing
- Vitamin B12 and Folic Acid
- Where
- Egypt
- Volunteers
- 50 people
- Sponsor
- Assiut University
Chronic Hepatitis C
Simplifying Hepatitis C Antiviral Therapy in Rwanda for Elsewhere in the Developing World
The main purpose of the study is to evaluate the efficacy, safety and tolerability of a medication, ledipasvir/sofosbuvir (LDV/SOF), used to treat individuals with chronic hepatitis C virus (HCV) in Rwandan adults.
- Trial name
- SHARED (NCT02964091)
- Testing
- sofosbuvir/ledipasvir
- Where
- Rwanda
- Volunteers
- 300 people
- Sponsor
- Partners in Health
Chronic Hepatitis C
A Study to Evaluate the Safety, Antiviral Effect, and Pharmacokinetics of Celgosivir in Combination With Peginterferon Alfa-2b and Ribavirin in Treatment-Naïve Patients With Chronic Hepatitis C
The objective of this study is to undertake an initial evaluation of the safety, tolerability, antiviral effect, and pharmacokinetics of celgosivir in combination with peginterferon alfa-2b and ribavirin in patients with chronic…
- Trial name
- NCT00332176
- Testing
- Celgosivir, Peginterferon alfa 2b + ribavirin
- Where
- 3 sites in Canada
- Volunteers
- 50 people
- Sponsor
- BioWest Therapeutics Inc
Hepatitis C Virus Infection, Chronic Hepatitis C
A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1, 2, 4, 5 or 6 Infection and Compensated Cirrhosis
The purpose of this study is to assess the safety and efficacy of ABT-493/ABT-530 following 12 weeks of treatment in adults with chronic Hepatitis C Virus Infection genotype 1, 2, 4, 5 or 6 infection and compensated cirrhosis.
- Conditions
- Hepatitis C Virus Infection, Chronic Hepatitis C, Compensated Cirrhosis
- Trial name
- EXPEDITION-1 (NCT02642432)
- Testing
- ABT-493/ABT-530
- Volunteers
- 146 people
- Sponsor
- AbbVie
Chronic Hepatitis C
A Randomized Trial of 24-Week Versus 48-Week Courses of Peginterferon Plus Ribavirin for Patients With Genotype 1 Hepatitis C and IL28B CC Polymorphism
Patients with HCV genotype 1 and IL28B CC Polymorphism who have a rapid virological response to treatment are randomised to either 24 or 48 weeks HCV treatment.
- Trial name
- NCT01441804
- Testing
- Peginterferon alfa2a, Ribavirin
- Where
- 4 sites in China
- Volunteers
- 200 people
- Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University
Hepatitis C Virus (HCV)
A Study of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment-Naive Adults With Chronic Hepatitis C Virus (HCV) Genotype 1-6 Infection and Compensated Cirrhosis
A Phase 3b, single arm, open-label, multicenter study in treatment naïve adults with chronic HCV infection and compensated cirrhosis to assess the safety of 8 weeks of treatment with glecaprevir/pibrentasvir and to demonstrate…
- Trial name
- EXPEDITION-8 (NCT03089944)
- Testing
- Glecaprevir/Pibrentasvir
- Where
- 113 sites in United States, Bulgaria and 17 more
- Volunteers
- 343 people
- Sponsor
- AbbVie
HIV Infections, Hepatitis C
Lopinavir/Ritonavir Monotherapy Versus Standard Highly Active Antiretroviral Therapy (HAART) in HIV/HCV Coinfected Patients Starting Treatment With Anti-Hepatitis C Virus (HCV) Therapy
The purpose of this study is to evaluate if the combination of Lpv/r monotherapy and anti-HCV drugs does not match with additional toxicity induced by the association of HAART and Peg-IFN + ritonavir in HIV/HCV coinfected…
- Trial name
- NCT00437684
- Testing
- LPV/r, PEG-IFNa 2a, Ribavirin
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- IRCCS San Raffaele
HIV Infection and Chronic Alanine Aminotransferase Elevation
Prevalence of Liver Fibrosis and Progression of Liver Fibrosis
Little is known about the clinical significance of chronic alanine aminotransferase (ALT) elevation in HIV-infected patients without hepatitis B and C coinfection.
- Trial name
- NCT01208376
- Testing
- Fibroscan
- Where
- Switzerland
- Volunteers
- 195 people
- Sponsor
- Helen Kovari-Kramer
Chronic Hepatitis C, Medication Reaction
The Efficacy of Vosevi in Treating DAA-experienced Patients
Hepatitis C virus (HCV) infection remains a significant health problem in our country. The World Health Organization estimated that 71 million people worldwide had chronic HCV infection in 2015.
- Trial name
- NCT06180590
- Testing
- Sofosbuvir / Velpatasvir / Voxilaprevir Oral Tablet [Vosevi]
- Where
- China
- Volunteers
- 200 people
- Sponsor
- The Third Affiliated Hospital of Guangzhou Medical University
Chronic Hepatitis B Virus Infection, Chronic Hepatitis C Virus Infection
Pharmacokinetic Study of BMS-914143 in Participants With Normal Renal Function and Mild, Moderate, Severe and End-stage Renal Dysfunction
The purpose of this study is to determine the effect of renal impairment on pharmacokinetics (PK) of BMS-914143.
- Trial name
- PK (NCT01708889)
- Testing
- BMS-914143 (Peginterferon Lambda-1a)
- Where
- 3 sites in United States
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Hepatitis C, Chronic, Hepatitis C
Evaluation of Patient Satisfaction in Hepatitis C Patients Treated With PegIntron Pen and Rebetol in Romania (Study P04301)
The objective of this study is to evaluate patient satisfaction in hepatitis C patients receiving PegIntron pen plus Rebetol. The rationale is that the effectiveness of treatment is correlated with adherence to the prescribed…
- Trial name
- NCT00704717
- Testing
- PegIntron (peginterferon alfa-2b; SCH 54031) pen, Rebetol (ribavirin; SCH 18908)
- Volunteers
- 185 people
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Hepatitis C
Simeprevir in Combination With Sofosbuvir in Treatment-Naïve or -Experienced Adults With Chronic Genotype 4 Hepatitis C Virus Infection
This study will look at the safety and efficacy of 8 week and 12 week treatment with Sofosbuvir and Simeprevir in treatment-naïve and treatment-experienced patients with chronic hepatitis C genotype 4.
- Trial name
- NCT02253550
- Testing
- Simeprevir, Sofosbuvir
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Peter J. Ruane, M.D.
Hepatitis C, Chronic, Hepatitis C
Patient Compliance During PegIntron and Rebetol Combination Therapy in Chronic Hepatitis C (Study P04690)
Participants will receive PegIntron injection pen (Peginterferon alfa-2b) and Rebetol (Ribavirin) combination therapy as their usual medical treatment.
- Trial name
- NCT00725205
- Testing
- PegIntron (Peginterferon alfa-2b), Rebetol (Ribavirin)
- Volunteers
- 294 people
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Hepatitis C
Boceprevir (SCH 503034) Plus Peg-Intron, With and Without Added Ribavirin, in Patients With Chronic Hepatitis C, Genotype 1, Who Did Not Respond to Previous Treatment With Peginterferon Alfa Plus Ribavirin (Study P03659AM2)(COMPLETED)
The primary objective of this study is to determine the safe and effective dose range of boceprevir (SCH 503034) in combination with PEG-Intron in adult subjects who have chronic hepatitis C without cirrhosis, and who have failed…
- Trial name
- NCT00160251
- Testing
- Boceprevir (BOC), PegIntron (PEG), Ribavirin (RBV)
- Volunteers
- 357 people
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Hepatitis C, Atherosclerosis
Hepatitis C Treatment and Atherosclerosis
This study will examine the effects of treatment for hepatitis C on atherosclerosis, or hardening of the arteries. Hepatitis C is a disease of the liver caused by a virus that can cause permanent damage to that organ.
- Trial name
- NCT00659256
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.